Cedrus Group, a Swiss global investment firm with a 15-year presence in China, recently completed its latest investment round in Hainan Leyun Biotechnology Co., Ltd., a Chinese scientific research and reproductive anti-aging company. The investment, amounting to several million dollars, further expands Cedrus' footprint in China.
With its huge population and vast middle class, the Chinese market continues to attract foreign capital. Cedrus Group is one of the many investors drawn to this dynamic market. At the opening ceremony of its Asia-Pacific Headquarters in May, the group announced plans to invest 1 billion yuan ($139.4 million) in developing healthcare and related innovative technologies on the Chinese mainland, including drug research and development, in vitro fertilization, and nanotechnology devices.
For the past 15 years, Cedrus has been committed to helping global companies navigate the highly competitive and complex life sciences industry, earning the trust of numerous partners. Given its preference for medical research in China, Cedrus has expanded its presence in first-tier cities such as Beijing, Shanghai, Hong Kong, and Shenzhen. Additionally, Cedrus plans to establish several private equity funds on the Chinese mainland this year, with an overall size exceeding 1.5 billion yuan.
Rani Jarkas, chairman of Cedrus Group, stated that over the years, Cedrus has gained unique insights into China's culture and market demand. The group's strategic direction aligns closely with China's national goals. In light of China's three-child policy, Cedrus has conducted in-depth research into the market for reproductive health and fertility products.
Founded in 2001, Cedrus provides private wealth management, investment management, and financial advisory services, focusing on life sciences, technology, natural resources and nanotechnology industries.
Cedrus' life sciences team and advisory board possess decades of experience and a good track record in executing successful investments in the sector. The team excels not only in investing in life sciences companies but also in providing comprehensive, customized strategic advice and investment banking services to life sciences companies worldwide.
The team comprises experts and physicians from top-tier medical institutions, hospitals, companies, and universities globally. With their expertise and experience, Cedrus' life sciences team has built a global life sciences network spanning China, Australia, Europe, and North America.
Hainan Leyun, a biotechnology company, focuses on transforming scientific research achievements in reproductive medicine. With the support of national key laboratory projects and the participation of expert teams from several renowned top-tier hospitals, Hainan Leyun successfully launched a series of reproductive nutrition supplements, including Dachao Reco18, Reju28, PCOS, and Dajing No. 1, to the market after five years of R&D. These products have filled the market gap for home-grown nutritional supplements in China, including hormone-free ovarian function conditioning, spermatic function conditioning, polycystic ovarian syndrome, and menopausal syndrome relief.
Dachao has now received substantial recognition and recommendations from gynecology and urology experts from major medical institutions in China. This financing round will further increase its investment in scientific research.
Commenting on the cooperation with Dachao series products, Jarkas said, "Cedrus prefers healthcare companies with strong innovation and scientific research capabilities when selecting investment targets and seeking cooperative relationships. It is clear that Dachao met Cedrus' criteria. It has great development potential in terms of its perceptiveness in the industry, the strength of the team, the investment in scientific research, and the derivatives of the brand. It merits a significant investment by Cedrus, and we are optimistic that there will be more in-depth cooperation between us in the future."
